Biocryst Pharmaceuticals INC Schedule 13G passive stakes

State Street Corporation has updated its Schedule 13G filing to reflect its beneficial ownership of 15,191,098 shares, or approximately 6%, of BioCryst Pharmaceuticals Inc. common stock as of June 30, 2026.

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioCryst Pharmaceuticals Inc. common stock as of March 31, 2026.

Vanguard Capital Management has disclosed a beneficial ownership of 5.16% of BioCryst Pharmaceuticals' common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in BioCryst Pharmaceuticals Inc. following an internal realignment.

Deerfield Mgmt, L.P. and its affiliates have reported a 6.81% beneficial ownership stake in BioCryst Pharmaceuticals, Inc. common stock.

State Street Corporation has reported a 5.3% beneficial ownership stake in BioCryst Pharmaceuticals Inc. common stock as of December 31, 2025.

RA Capital Management and its affiliates have reported a 7.3% passive ownership stake in BioCryst Pharmaceuticals, Inc., holding over 15 million shares.

Deerfield Management and its affiliates have disclosed a 5.80% beneficial ownership stake in BioCryst Pharmaceuticals, Inc., totaling 12,169,000 common shares.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a beneficial ownership of 4.2% in BioCryst Pharmaceuticals Inc., totaling 8.7 million shares.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.4% of BioCryst Pharmaceuticals Inc.'s common stock as of March 31, 2025.